If you participate in developing your cancer program’s short- and long-term strategic goals, you cannot afford to miss the ACCC 51st Annual Meeting & Cancer Center Business Summit (AMCCBS), March 5–7, 2025, in Washington, DC. This summit is more than a conference—it’s your roadmap to staying ahead in a rapidly evolving healthcare landscape. Here’s how it can help shape your strategic planning:

Short-Term Gains

• Leverage AI and BI for Operational Excellence (Deep Dive 1): Learn how Sarasota Memorial Health Care and Oklahoma Cancer Specialists use AI and business intelligence tools to improve workflows, increase early cancer detection rates, and achieve a significant return on investment. Walk away with actionable insights to implement immediately.
• Increase Revenue and Improve Access (Deep Dive 2): Discover how Texas Oncology’s innovative virtual APP visits have expanded patient access, reduced out-of-pocket costs, and generated additional revenue. This scalable model serves over 90 sites of service, demonstrating how virtual care solutions can be seamlessly integrated into your practice.
• Boost Referrals and Expedite Treatment (Deep Dive 2): Learn how Munson Healthcare’s Oncology Diagnostic Clinic piloted a successful program to reduce time to treatment by coordinating directly with emergency departments and primary care providers. Their strategic use of resources resulted in faster intervention for underserved patients and increased referral volumes.

Long-Term Vision

• Understand Future Cancer Care Trends: Nick Webb’s keynote, The Future of Cancer Care Delivery: 2025 and Beyond, will outline transformative trends like hyper-consumerization and advanced technology integration that will shape the oncology landscape for years to come.
• Build Strategic Partnerships (Deep Dive 3): Explore case studies of successful affiliations between academic and community programs, with insights on legal and operational considerations.
• Innovate in Community Engagement (Deep Dive 7): Learn from Mary Bird Perkins Cancer Center’s mobile cancer screening implementation playbook, offering strategies to improve equity, detection rates, and early treatment outcomes.

Tailored Insights for Decision-Makers

• Gain evidence-based tools to refine leadership and operational strategies in Evidence-Based Decision-Making in Healthcare Management and Leadership (Friday session).
• Learn growth strategies and marketplace differentiation tactics from leaders at Dana-Farber, Inova Schar Cancer, and more in a powerful Friday panel.

With topics ranging from cutting-edge technologies to financial optimization and service line growth, this summit will provide you with the knowledge and connections needed to future-proof your organization. Don’t miss this opportunity to shape your strategic path. Register today and join thought leaders in cancer care in these important discussions.

Insights From ACORI’s Community Oncology Inclusive Clinical Trial Design Summit

The ACCC Community Oncology Research Institute (ACORI) Summit held in October of 2024 outlined a comprehensive strategy to improve inclusion in oncology clinical trial design. Key stakeholders discussed the potential for artificial intelligence innovations to enhance decision-making and foster collaboration across cancer centers to increase trial opportunities and participation. Additionally, integrating advanced practice providers as principal investigators in clinical trials can expand diversity and build capacity in community practices. By refining trial oversight, decentralizing trials, and revisiting restrictive inclusion/exclusion criteria, we can make clinical trials more inclusive, efficient, and patient-centered. These important conversations will continue at AMCCBS in Deep Dive 4: Research and Clinical Trials.

Adverse Event Management for CDK Inhibitors in Hormone Receptor–Positive Breast Cancer

Learn how CDK inhibitors can help manage hormone receptor-positive breast cancer by targeting overactive proteins that drive uncontrolled cell growth, significantly improving progression free survival and overall outcomes, particularly when combined with endocrine therapy. However, treatment-related adverse events like gastrointestinal symptoms, neutropenia, and anemia require proactive management to ensure adherence and maintain quality of life. Managing these potential adverse events is imperative to ensure patients remain on therapy and avoid unnecessary discontinuation. Explore this comprehensive infographic with essentials like dosage recommendations, potential side effects, and how to consult patients with breast cancer on managing their symptoms for effective therapy management.

Treatment for Double-Exposed CLL Management

Patients with chronic lymphocytic leukemia who fail to respond to both Bruton tyrosine kinase inhibitors and B-cell lymphoma 2 inhibitors often experience poorer outcomes, highlighting the need for tailored treatment strategies. In recognition of this challenge, particularly within community practices, ACCC developed a guide to help clinicians navigate the complexities of treating these patients. The resource emphasizes the importance of individualized care, considering factors such as genomic risk, prior therapies, comorbidities, frailty, and patient goals. With a focus on shared decision-making, it encourages engaging patients in discussions about their priorities to determine the most appropriate next steps. This patient-centered approach ensures that treatment plans align with individuals’ needs, preferences, and quality of life while fostering multidisciplinary collaboration to optimize care and outcomes.